| Bioactivity | Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2]. |
| Invitro | Ziv-aflibercept (0.25、0.5、1.0 和 5 mg/mL；24 h) 以剂量依赖性方式降低 ARPE-19 细胞的线粒体膜电位[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | Ziv-aflibercept (25 mg/mL；眼内注射；单剂量) 在兔子右眼中没有显著引起白内障、视网膜脱离等相关并发症[2]。 |
| Name | Ziv-aflibercept |
| CAS | 1609655-49-3 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. [2]. de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3. |